Role of a Clinical Pharmacist on Drotrecogin Alfa (activated) Outcomes in a Large Community Teaching Hospital

Author： Kotapati Srividya   Kuti Joseph L.   Nicolau David  

Publisher： Haworth Press

ISSN： 1068-7777

Source： Journal of Infectious Disease Pharmacotherapy, Vol.6, Iss.3, 2004-01, pp. : 55-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drotrecogin Alfa (Activated)

By Lyseng-Williamson K.A.   Perry C.M.  

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 617-630

Adis International

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi

By Levi M.  

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 631-632

Adis International

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

By Frampton J.E.   Foster R.H.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 445-476

Adis International

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

By McCoy Christopher  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 625-637

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis

By Daniel De Backer  

Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. : 995-1010

Adis International

Access to resources Recommend Favorite